Calvin Roberts - Auris Medical Non-Executive Independent Director

Director

Dr. Calvin W. Roberts, M.D., serves as NonExecutive Independent Director of Auris Medical Holding Ltd. Dr. Roberts was elected to our board of directors in 2015 since 2015.
Age 62
Tenure 9 years
Professional MarksPh.D
Phone441 295 5950
Webhttp://www.aurismedical.com
Roberts, M.D., is Chief Medical Officer at Bausch + Lomb and Senior Vice President and Chief Medical Officer, Eye Care of Valeant Pharmaceuticals. He joined Bausch + Lomb in 2011. Dr. Roberts is a specialist in cataract and refractive surgery and was a pioneer in the use of ophthalmic nonsteroidals. Since 1982 he was a Clinical Professor of Ophthalmology at Weill Medical College of Cornell University; in addition, he had a private ophthalmology practice in New York City between 1998 and 2008. He is the author of over 50 peerreviewed articles. Dr. Roberts was a member of the Board of Directors and the Audit Committee of Alimera Sciences, Inc., since it was founded in 2003.

Auris Medical Management Efficiency

The company has return on total asset (ROA) of (21.99) % which means that it has lost $21.99 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (71.91) %, meaning that it created substantial loss on money invested by shareholders. Auris Medical's management efficiency ratios could be used to measure how well Auris Medical manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 523.92 K in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Auris Medical Holding has a current ratio of 3.75, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Auris Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Auris Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Auris Medical Holding sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Auris to invest in growth at high rates of return. When we think about Auris Medical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Ricardo ToucheGrupo Aeroportuario del
72
Carlos CollGrupo Aeroportuario del
56
Mona StephensonPentair PLC
58
Randall BortVerra Mobility Corp
51
Rasmus ChristiansenGrupo Aeroportuario del
68
Roberto SendraGrupo Aeroportuario del
91
William PattonVerra Mobility Corp
70
Aurelio AlonsoGrupo Aeroportuario del
48
Theodore HarrisPentair PLC
56
Agustin RodriguezGrupo Aeroportuario del
57
Francisco ZambranoGrupo Aeroportuario del
64
Edward GardenPentair PLC
54
Carol DavidsonPentair PLC
60
Billie WilliamsonPentair PLC
68
Hector MunozGrupo Aeroportuario del
63
William MonahanPentair PLC
68
Glynis BryanPentair PLC
62
Michael GlennPentair PLC
62
Ronald MerrimanPentair PLC
73
Luis PardoGrupo Aeroportuario del
69
Jeffrey ReaVerra Mobility Corp
53
Auris Medical Holding Ltd., a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. Auris Medical Holding Ltd. was founded in 1998 and is headquartered in Hamilton, Bermuda. Auris Medical operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. Auris Medical Holding (EARS) is traded on NASDAQ Exchange in USA and employs 8 people.

Management Performance

Auris Medical Holding Leadership Team

Elected by the shareholders, the Auris Medical's board of directors comprises two types of representatives: Auris Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Auris. The board's role is to monitor Auris Medical's management team and ensure that shareholders' interests are well served. Auris Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Auris Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Cindy McGee, Head of Investor Relations and Corporate Communications
Hernan Levett, CFO
James Healy, Non-Executive Independent Vice Chairman of the Board
Bettina Stubinski, Chief Medical Officer
Thomas Meyer, Founder, Chairman, CEO and Managing Director
Calvin Roberts, Non-Executive Independent Director
Wolfgang Arnold, Board Member
Oliver Kubli, Board Member
Thomas Jung, Chief Development Officer
Andrea Braun, Head of Regulatory and Quality Affairs
Mats Blom, Director
Antoine Papiernik, Non-Executive Independent Director
Anne Zoller, General Counsel
Berndt Modig, Non-Executive Independent Director
Sven Zimmermann, CFO
Armando Anido, Non-Executive Independent Director
Alain Munoz, Director

Auris Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Auris Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Auris Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Auris Medical's short interest history, or implied volatility extrapolated from Auris Medical options trading.

Pair Trading with Auris Medical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Auris Medical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Auris Medical will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Perrigo Company could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Perrigo Company when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Perrigo Company - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Perrigo Company PLC to buy it.
The correlation of Perrigo Company is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Perrigo Company moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Perrigo Company moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Perrigo Company can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Consideration for investing in Auris Stock

If you are still planning to invest in Auris Medical Holding check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Auris Medical's history and understand the potential risks before investing.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Fundamental Analysis
View fundamental data based on most recent published financial statements